Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has received an average rating of "Moderate Buy" from the ten research firms that are currently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $11.43.

Several analysts recently commented on AMLX shares. Robert W. Baird raised Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $3.00 to $11.00 in a research note on Monday, November 18th. Leerink Partners set a $4.00 price target on Amylyx Pharmaceuticals and gave the stock a "market perform" rating in a report on Friday, October 18th. Bank of America upgraded Amylyx Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $4.20 to $10.00 in a report on Wednesday, October 23rd. Baird R W raised Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Finally, HC Wainwright lifted their price target on shares of Amylyx Pharmaceuticals from $8.00 to $12.00 and gave the company a "buy" rating in a research note on Friday, November 8th.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, Director George M. Milne, Jr. purchased 100,000 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were purchased at an average cost of $2.20 per share, with a total value of $220,000.00. Following the transaction, the director now directly owns 858,571 shares of the company's stock, valued at $1,888,856.20. This represents a 13.18 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Camille L. Bedrosian sold 11,442 shares of the firm's stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $3.20, for a total value of $36,614.40. Following the completion of the transaction, the insider now owns 143,801 shares of the company's stock, valued at $460,163.20. The trade was a 7.37 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.70% of the company's stock.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in AMLX. Vanguard Group Inc. lifted its stake in Amylyx Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,348,139 shares of the company's stock valued at $15,189,000 after purchasing an additional 72,573 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Amylyx Pharmaceuticals by 2,768.0% during the 2nd quarter. AQR Capital Management LLC now owns 3,340,943 shares of the company's stock worth $6,348,000 after acquiring an additional 3,224,454 shares during the period. abrdn plc increased its holdings in shares of Amylyx Pharmaceuticals by 1,567.9% during the 3rd quarter. abrdn plc now owns 1,972,242 shares of the company's stock worth $6,390,000 after acquiring an additional 1,853,995 shares during the last quarter. Almitas Capital LLC bought a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at $3,617,000. Finally, Acadian Asset Management LLC bought a new position in Amylyx Pharmaceuticals during the second quarter worth $2,300,000. Institutional investors own 95.84% of the company's stock.

Amylyx Pharmaceuticals Price Performance

AMLX traded down $0.21 during mid-day trading on Tuesday, hitting $5.45. The stock had a trading volume of 714,128 shares, compared to its average volume of 2,006,372. The stock's fifty day simple moving average is $4.49 and its 200-day simple moving average is $2.86. The firm has a market capitalization of $373.60 million, a price-to-earnings ratio of -1.43 and a beta of -0.70. Amylyx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $19.95.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.